蛋白酪氨酸激酶

CAS号：1140909-48-3

品名：卡博替尼苹果酸盐CabozantinibS-Malate

中文别名：苹果酸卡博替尼;

英文别名：cyclopropane-1,1-dicarboxylicacid[4-(6,7-dimethoxyquinoline-4-yloxy)phenyl]amide(4-fluoro-phenyl)amide(L)-malatesalt;Cabozantinibmalate(XL184);Cabozantinibmalate;Cabozantinibmalatesalt;UNII-DR7ST46X58;cyclopropane-1,1-dicarboxylicacid[4-(6,7-dimethoxy-quinoline-4-yloxy)-phenyl]-amide(4-fluoro-phenyl)-amideL-malate;N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide(L)malate;Cometriq;Cabozantinibs-malate[USAN];XL184;CabozantinibL-MalateSalt;N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide(L)-malatesalt;Cabozantinib(XL184);1-N-[4-(6,7-dimethoxyquinolin-4-yl)oxyphenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,(2S)-2-hydroxybutanedioicacid;

分子式：C32H30FN3O10

分子量：635.593

精确质量：635.192

Psa：193.61

UNII号：DR7ST46X58

密度：

储存条件：室温，干燥，密封

简介：CabozantinibisasmallmoleculeC-Metmodulator.CabozantinibactsasapotentmultitargetedVEGFR2,Met,FLT3,Tie2,KitandRetinhibitorwithIC50of0.035,1.8,14.4,14.3and4.6nMforVEGFR2,Met,FLT3,Tie2andKit,respectively.Cabozantinibshowsdose-dependentinhibitionoftumorgrowthandtumorregression,associatedwithdisruptionofthetumorvasculatureandextensivetumorcellapoptosis.

其他分子

CAS号：61-80-3

品名：2-氨基-5-氯苯并噁唑2-Amino-5-chlorobenzoxazole

中文别名：苯并恶唑胺;氯苯唑胺;

英文别名：2-Benzoxazolamine,5-chloro-;5-chloro-1,3-benzoxazol-2-amine;

分子式：C7H5ClN2O

分子量：168.58

精确质量：168.009

Psa：52.05

RTECS号：DM4550000

MDL号：MFCD00005770

密度：1.481 g/cm3

沸点：316.8ºC at 760 mmHg

熔点：181-184°C(lit.)

闪点：145.4ºC

折射率：1.692

储存条件：库房通风低温干燥

安全说明：S26-S36

危险类别码：R20/21/22; R36/37/38

WGK Germany：3

海关编码：2934999090

危险品标志：Xn

信号词：Warning

危险性防范说明：P261; P280; P305 + P351 + P338

危险标志：GHS07

危险性描述：H302; H312; H315; H319; H332; H335

简介：Zoxazolamine(INN,USAN,BAN)(brandnameContrazole,Deflexol,Flexin,Miazol,Uri-Boi,Zoxamine,Zoxine)isamusclerelaxantthatisnolongermarketed.Itwassynthesizedin1953andintroducedclinicallyin1955butwaswithdrawnduetohepatotoxicity.Oneofitsactivemetabolites,chlorzoxazone,wasfoundtoshowlesstoxicity,andwassubsequentlymarketedinplaceofzoxazolamine.ThesedrugsactivateIKCachannels.